Splenectomy following JAK1/JAK2 inhibitor therapy in patients with myelofibrosis undergoing allogeneic stem cell transplantation

Background: Allogeneic hematopoietic stem cell transplantation (alloHSCT) is the only treatment option with curative potential in patients with myelofibrosis (MF). The aim of our study was to evaluate the safety of splenectomy before alloHSCT in MF patients who failed to achieve significant spleen r...

Descripción completa

Detalles Bibliográficos

Autores principales:	Maria Vladimirovna Barabanshikova, Igor Nikolaevich Zubarovsky, Vjacheslav Mikhailovich Savrasov, Andrey Jurjevich Korolkov, Vadim Valentinovich Baykov, Anna Vjacheslavovna Botina, Julia Jurjevna Vlasova, Ivan Sergeevich Moiseev, Elena Igorevna Darskaya, Elena Vladislavovna Morozova, Boris Vladimirovich Afanasyev
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Wolters Kluwer Medknow Publications 2019-07-01
Colección:	Hematology/Oncology and Stem Cell Therapy
Materias:	allogeneic hematopoietic stem cell transplantation myelofibrosis ruxolitinib splenectomy
Acceso en línea:	https://journals.lww.com/10.1016/j.hemonc.2019.03.001
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!